BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dermatomyositis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Dermatomyositis\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07089121-3307@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Descartes-08: Phase 1/2 readout est. (NCT07089121)
DESCRIPTION:Descartes-08\, phase 1/2\, Myasthenia Gravis.\nStudy: Descartes
 -08 for Children\, Adolescents\, and Young Adults With Autoimmune Disorder
 s\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/descartes-08#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07089121
URL:https://assetmemo.bio/drug/descartes-08#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05895786-5753@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20300729
DTEND;VALUE=DATE:20300730
SUMMARY:PF-06823859: Phase 3 readout est. (NCT05895786)
DESCRIPTION:PF-06823859\, phase 3\, Dermatomyositis.\nStudy: A Study to Und
 erstand How the Study Medicine (PF-06823859) Works in People With Active I
 diopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (
 PM)]\nEstimated primary completion: 29 July 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pf-06823859#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05895786
URL:https://assetmemo.bio/drug/pf-06823859#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698796-5753@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20310729
DTEND;VALUE=DATE:20310730
SUMMARY:PF-06823859: Phase 3 readout est. (NCT06698796)
DESCRIPTION:PF-06823859\, phase 3\, Dermatomyositis.\nStudy: A Study to Und
 erstand How the Study Medicine Dazukibart Works in People With Idiopathic 
 Inflammatory Myopathies\nEstimated primary completion: 29 July 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pf-06823859#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06698796
URL:https://assetmemo.bio/drug/pf-06823859#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
